Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.

Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S.

J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78. doi: 10.1097/FJC.0000000000000091.

PMID:
24621652
2.

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.

Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G.

Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.

3.

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B.

Handb Exp Pharmacol. 2017;243:271-305. doi: 10.1007/164_2016_76. Review.

PMID:
27830348
4.

Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.

Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA.

Expert Opin Investig Drugs. 2015;24(8):1123-35. doi: 10.1517/13543784.2015.1059819. Epub 2015 Jun 20. Review.

PMID:
26095025
5.

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.

Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B, Klopfleisch R, Foryst-Ludwig A, Kolkhof P, Kintscher U.

J Cardiovasc Pharmacol. 2016 May;67(5):402-11. doi: 10.1097/FJC.0000000000000366.

PMID:
26859196
6.

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.

Arai K, Tsuruoka H, Homma T.

Eur J Pharmacol. 2015 Dec 15;769:266-73. doi: 10.1016/j.ejphar.2015.11.028. Epub 2015 Nov 26.

PMID:
26607463
7.

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J.

J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22.

8.

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.

Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J.

Hypertension. 2017 May;69(5):870-878. doi: 10.1161/HYPERTENSIONAHA.116.08526. Epub 2017 Mar 20.

PMID:
28320854
9.

A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.

Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T; ARTS-HF Japan study group.

Circ J. 2016 Apr 25;80(5):1113-22. doi: 10.1253/circj.CJ-16-0122. Epub 2016 Apr 14.

10.

Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.

Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE.

Eur J Heart Fail. 2016 Jan;18(1):28-37. doi: 10.1002/ejhf.444. Epub 2015 Dec 3. Review. Erratum in: Eur J Heart Fail. 2017 Jun;19(6):811.

11.

Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.

Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jaisser F, Ouvrard-Pascaud A.

Hypertension. 2016 Apr;67(4):717-23. doi: 10.1161/HYPERTENSIONAHA.115.06709. Epub 2016 Feb 22.

12.

Renin-angiotensin system blockade: Finerenone.

Ruilope LM, Tamargo J.

Nephrol Ther. 2017 Apr;13 Suppl 1:S47-S53. doi: 10.1016/j.nephro.2017.02.003. Review.

PMID:
28577743
13.

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.

Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET.

Hypertension. 2008 Aug;52(2):295-300. doi: 10.1161/HYPERTENSIONAHA.107.109645. Epub 2008 Jun 30.

14.

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, Sada T.

Eur J Pharmacol. 2015 Aug 15;761:226-34. doi: 10.1016/j.ejphar.2015.06.015. Epub 2015 Jun 11.

PMID:
26073023
15.

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

Dutzmann J, Musmann RJ, Haertlé M, Daniel JM, Sonnenschein K, Schäfer A, Kolkhof P, Bauersachs J, Sedding DG.

PLoS One. 2017 Sep 19;12(9):e0184888. doi: 10.1371/journal.pone.0184888. eCollection 2017.

16.

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P.

ChemMedChem. 2012 Aug;7(8):1385-403. doi: 10.1002/cmdc.201200081. Epub 2012 Jul 12.

PMID:
22791416
17.

Eplerenone: a selective aldosterone receptor antagonist (SARA).

Delyani JA, Rocha R, Cook CS, Tobert DS, Levin S, Roniker B, Workman DL, Sing YL, Whelihan B.

Cardiovasc Drug Rev. 2001 Fall;19(3):185-200. Review.

PMID:
11607037
18.

Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.

Zhou X, Crook MF, Sharif-Rodriguez W, Zhu Y, Ruben Z, Pan Y, Urosevic-Price O, Wang L, Flattery AM, Forrest G, Szeto D, Zhao H, Roy S, Forrest MJ.

Clin Exp Hypertens. 2011;33(8):538-47. doi: 10.3109/10641963.2011.566956. Epub 2011 Sep 27.

19.

Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.

Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009. Epub 2009 Jun 17.

20.

Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.

Enomoto S, Yoshiyama M, Omura T, Matsumoto R, Kusuyama T, Kim S, Izumi Y, Akioka K, Iwao H, Takeuchi K, Yoshikawa J.

Heart. 2005 Dec;91(12):1595-600. Epub 2005 Mar 29.

Supplemental Content

Support Center